A budget impact analysis of natalizumab use in Ireland.

Hdl Handle:
http://hdl.handle.net/10147/146377
Title:
A budget impact analysis of natalizumab use in Ireland.
Authors:
Dee, A; Hutchinson, M; De La Harpe, D
Affiliation:
Department of Public Health, HSE-Mid West, Mount Kennett House, Henry Street, Limerick, Ireland, anne.dee1@hse.ie.
Citation:
A budget impact analysis of natalizumab use in Ireland. 2011:notIr J Med Sci
Journal:
Irish journal of medical science
Issue Date:
20-Oct-2011
URI:
http://hdl.handle.net/10147/146377
DOI:
10.1007/s11845-011-0773-6
PubMed ID:
22012552
Abstract:
BACKGROUND: Multiple sclerosis is the commonest cause of disability in young Irish adults. Natalizumab reduces disability progression in those patients with relapsing remitting multiple sclerosis who are suitable for it. First line disease modifying therapies are given in the community and are paid for by the hi-tech drug scheme. Natalizumab is given in hospital and is paid for from the hospital's budget. Access to natalizumab has been problematic in some Irish hospitals. A budget impact analysis was performed to look at the overall cost to the Health Service Executive of giving natalizumab. METHODS: A budget impact analysis was performed from the perspective of the Health Service Executive comparing the use of natalizumab with first line disease modifying therapies for 2009-2011. RESULTS: The study showed that currently, the use of natalizumab is likely to be cost saving to the Health Service Executive overall, because some of the costs for natalizumab are borne by private insurers, whereas, all of the costs of disease modifying therapies are borne by the Health Service Executive. CONCLUSIONS: Although the use of natalizumab is cost saving, current funding arrangements in the Health Service Executive do not allow for the transfer of money saved from drugs paid for in the hi-tech scheme, to hospitals who are supplying alternative treatments.
Item Type:
Article
Language:
en
Keywords:
HEALTH PROTECTION
Local subject classification:
PUBLIC HEALTH DEPARTMENT; HEALTH SERVICE PLANNING
ISSN:
1863-4362

Full metadata record

DC FieldValue Language
dc.contributor.authorDee, Aen
dc.contributor.authorHutchinson, Men
dc.contributor.authorDe La Harpe, Den
dc.date.accessioned2011-10-21T13:35:13Z-
dc.date.available2011-10-21T13:35:13Z-
dc.date.issued2011-10-20-
dc.identifier.citationA budget impact analysis of natalizumab use in Ireland. 2011:notIr J Med Scien
dc.identifier.issn1863-4362-
dc.identifier.pmid22012552-
dc.identifier.doi10.1007/s11845-011-0773-6-
dc.identifier.urihttp://hdl.handle.net/10147/146377-
dc.description.abstractBACKGROUND: Multiple sclerosis is the commonest cause of disability in young Irish adults. Natalizumab reduces disability progression in those patients with relapsing remitting multiple sclerosis who are suitable for it. First line disease modifying therapies are given in the community and are paid for by the hi-tech drug scheme. Natalizumab is given in hospital and is paid for from the hospital's budget. Access to natalizumab has been problematic in some Irish hospitals. A budget impact analysis was performed to look at the overall cost to the Health Service Executive of giving natalizumab. METHODS: A budget impact analysis was performed from the perspective of the Health Service Executive comparing the use of natalizumab with first line disease modifying therapies for 2009-2011. RESULTS: The study showed that currently, the use of natalizumab is likely to be cost saving to the Health Service Executive overall, because some of the costs for natalizumab are borne by private insurers, whereas, all of the costs of disease modifying therapies are borne by the Health Service Executive. CONCLUSIONS: Although the use of natalizumab is cost saving, current funding arrangements in the Health Service Executive do not allow for the transfer of money saved from drugs paid for in the hi-tech scheme, to hospitals who are supplying alternative treatments.-
dc.languageENG-
dc.language.isoenen
dc.subjectHEALTH PROTECTIONEN
dc.subject.otherPUBLIC HEALTH DEPARTMENTEN
dc.subject.otherHEALTH SERVICE PLANNINGEN
dc.titleA budget impact analysis of natalizumab use in Ireland.en
dc.typeArticleen
dc.contributor.departmentDepartment of Public Health, HSE-Mid West, Mount Kennett House, Henry Street, Limerick, Ireland, anne.dee1@hse.ie.en
dc.identifier.journalIrish journal of medical scienceen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.